The prevalence of U.S. adult smoking declined to 19.3 percent in 2017

, ,

On Nov. 9, 2918, the U.S. Centers for Disease Control and Prevention (CDC) reported an estimated 47.4 million U.S. adults (19.3%) currently used any tobacco product. Among current tobacco product users, 86.7% (41.1 million) smoked combustible tobacco products, and 19.0% (9.0 million) used two or more tobacco products.

In 2017, an estimated 47.4 million U.S. adults (19.3%) currently used any tobacco product. Among current tobacco product users, 86.7% (41.1 million) smoked combustible tobacco products, and 19.0% (9.0 million) used two or more tobacco products.

Cigarette smoking harms nearly every organ of the body and causes adverse health consequences, including heart disease, stroke, and multiple types of cancer.

The findings in this report are subject to at least four limitations. First, the potential for recall bias exists because responses were self-reported and not biochemically validated. However, self-reported smoking status correlates highly with serum cotinine levels. Second, the questionnaire did not assess gender identity; including transgender persons could affect overall tobacco use estimates among the sexual and gender minorities considered in this report. Third, NHIS estimates are not generalizable to persons in the military or institutionalized populations. Finally, the NHIS Sample Adult component’s response rate of 53.0% might have resulted in nonresponse bias.

Full implementation of comprehensive tobacco control programs at the national, state, and local levels, including tobacco price increases, high-impact anti-tobacco mass media campaigns, comprehensive smoke-free laws, and barrier-free access to tobacco cessation counseling and approved medications, along with FDA regulation of tobacco products, can accelerate progress toward reducing tobacco-related death and disease in the United States.

Tags:


Source: U.S. Centers for Disease Control and Prevention
Credit:

bioinnovatise accelerates scientific discovery by providing fast, reliable, and high-quality CDMO services for plasmid DNA and viral vector-based research.